Perez David Brian 4

What Happened

• David Brian Perez, a director of Neogenomics, reported transactions on 2026-06-01 showing: exercise/conversion of 23,077 derivative shares (code M) and the release/grant of 11,069 and 15,970 shares (codes A) from previously awarded restricted stock units (RSUs). The filing shows a $0.00 per-share price for these entries, indicating conversion/award treatment rather than an open-market cash purchase or sale.
• Totals: 50,116 shares were listed as acquired in the filing (23,077 + 11,069 + 15,970). Because the 23,077 derivative shares are also listed as disposed, the net increase to Perez’s holdings from these transactions is 27,039 shares (the RSU releases).

Key Details

• Transaction date(s): 2026-06-01; SEC Form 4 filed: 2026-06-03 (appears timely for a 2-business-day filing window).
• Reported prices: $0.00 per share for all reported entries (reflects conversion/award, not a cash purchase or sale).
• Specifics: 23,077 shares — exercise/conversion of a derivative (M) acquired and simultaneously disposed (M); 11,069 and 15,970 shares — grants/release of RSUs (A) acquired.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes: F1 — the RSU releases reflect restricted stock units previously reported on a Form 4; F2 — once vested, these common shares are not subject to expiration.

Context

• The M code denotes exercise or conversion of a derivative; the filing shows equal amounts acquired and disposed for the 23,077-share entry, which typically indicates immediate settlement or netting at exercise rather than a long-term hold. The A-code entries are RSU releases (awards) that increase holdings without an open-market purchase.
• These are awards/conversions, not open-market buys or gifts; factual reporting of such awards does not by itself indicate an intent to buy or sell stock on the open market.